NCT07104149 is a Phase 2 clinical trial of Cadonilimab combined with cisplatin in Female, Age ≥ 18 Years Old, sponsored by The First Affiliated Hospital of Zhengzhou University.

Who is sponsoring NCT07104149?

NCT07104149 is sponsored by The First Affiliated Hospital of Zhengzhou University.

What drugs are being tested in NCT07104149?

Interventions in NCT07104149: Cadonilimab combined with cisplatin.

What condition does NCT07104149 study?

NCT07104149 studies Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy, ECOG Score of 0-1, Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion, Sufficient Organ Function, The Result of the Urine or Serum Pregnancy Test for the Subject is Negative, Subjects Should Take Contraceptive Measures, Locally Advanced Cervical Cancer, Expected Survival Time >6 Months.

Is NCT07104149 still recruiting?

NCT07104149 is currently recruiting now. Last updated 5 August 2025.

Last reviewed 2025-08-05 · How we verify

NCT07104149

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Recruiting now Phase 2 Last updated 5 August 2025

What this trial tests

Phase 2 trial testing Cadonilimab combined with cisplatin in Female, Age ≥ 18 Years Old in 29 participants. Currently enrolling.

Timeline

10 March 2025

Primary endpoint
31 December 2026

30 June 2027

Quick facts

Lead sponsor	The First Affiliated Hospital of Zhengzhou University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	10 March 2025
Primary completion	31 December 2026
Estimated completion	30 June 2027
Sites	1 location across China

Drugs / interventions tested

Cadonilimab combined with cisplatin — full drug profile →

Conditions studied

Female, Age ≥ 18 Years Old — all drugs for Female, Age ≥ 18 Years Old →
No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy — all drugs for No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy →
ECOG Score of 0-1 — all drugs for ECOG Score of 0-1 →
Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion — all drugs for Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion →

Sponsor

The First Affiliated Hospital of Zhengzhou University

Who can join

Adults 18 to 75, female only, with Female, Age ≥ 18 Years Old or No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Main Purpose of this study is to determine the efficacy and safety of Cadonilimab combined with chemotherapy (cisplatin) for locally advanced cervical cancer. This is an multicentre, single Arm, Phase 2 Trial study of Cadonilimab with Cisplatin in the treatment of locally advanced cervical cancer. 29 eligible patients will receive Cadonilimab（10mg/kg, iv., D1, q3w）with Cisplatin ( 75mg/ m2, iv., D2， q3w) for a total of 2-4 cycles before radical surgical treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other The First Affiliated Hospital of Zhengzhou University trials

Trials by the same sponsor.

NCT07501962 — Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate · NA · not yet recruiting
NCT07501975 — Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality · NA · not yet recruiting
NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
NCT07314619 — Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combi · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07104149 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Zhengzhou University
Last refreshed: 5 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07104149.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing